Senti Biosciences Holdings (SNTI) Liabilities and Shareholders Equity (2021 - 2025)

Senti Biosciences Holdings' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $51.2 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 47.65% year-over-year to $51.2 million; the TTM figure through Dec 2025 stood at $255.2 million (down 25.95% YoY), while the FY2025 annual figure was $51.2 million, down 47.65% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $51.2 million, down from $52.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $231.9 million in Q2 2021, with the low at $373657.0 in Q1 2021.
• The 5-year median for Liabilities and Shareholders Equity is $110.8 million (2023), against an average of $126.0 million.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 61698.89% in 2022, then slumped 56.19% in 2024.
• Senti Biosciences Holdings' Liabilities and Shareholders Equity stood at $96.7 million in 2021, then jumped by 86.96% to $180.8 million in 2022, then tumbled by 33.91% to $119.5 million in 2023, then fell by 18.11% to $97.8 million in 2024, then sank by 47.65% to $51.2 million in 2025.
• Business Quant data shows SNTI's Liabilities and Shareholders Equity at $51.2 million in Q4 2025, $52.7 million in Q3 2025, and $68.5 million in Q2 2025.